Filing Overview
Registrant: Enochian Biosciences Inc. and subsidiaries, not Lunai Bioworks Inc. The supplied filing is an unaudited Form 10-Q for the quarter and nine months ended March 31, 2023, filed May 12, 2023. The request metadata identifies “Lunai Bioworks Inc.” and “2022 Q3,” which does not match the filing text.
The company is a pre-revenue biotechnology developer focused on cell and gene therapies for oncology, HIV, HBV and other infectious diseases. Current development priorities are the oncology platform, particularly ENOB-DC11, and the HIV therapeutic vaccine ENOB-HV12.
Financial Results and Position
| Metric | Three months ended March 31, 2023 | Three months ended March 31, 2022 | Nine months ended March 31, 2023 | Nine months ended March 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Total operating expenses | $4.06 million | $4.03 million | $15.62 million | $17.87 million |
| Operating loss | $4.06 million | $4.03 million | $15.62 million | $17.87 million |
| Net loss | $4.33 million | $6.20 million | $16.49 million | $23.20 million |
| Basic and diluted loss per share | $0.08 | $0.12 | $0.30 | $0.44 |
| Cash used in operating activities | Not separately provided | Not separately provided | $9.51 million | $12.68 million |
Operating expenses in the quarter were essentially flat year over year. General and administrative expense increased 36% to $3.80 million, while research and development expense declined 80% to $239,000. For the nine-month period, operating expenses declined 13%, primarily because of lower research and development spending.
Other expense was $265,000 for the quarter and $864,000 for the nine-month period. The prior-year periods included non-cash changes in the fair value of contingent consideration of $2.08 million and $5.07 million, respectively. Interest expense increased to $122,000 for the quarter and $311,000 for the nine-month period.
| Balance-sheet metric | March 31, 2023 | June 30, 2022 |
|---|---|---|
| Cash | $2.95 million | $9.17 million |
| Working capital | $(7.85) million | $3.11 million |
| Total assets | $78.73 million | $84.63 million |
| Total liabilities | $12.60 million | $12.01 million |
| Stockholders’ equity | $66.13 million | $72.62 million |
| Accumulated deficit | $220.83 million | $204.35 million |
Debt included $4.80 million of notes payable classified as current and $1.20 million of convertible notes payable. The convertible notes were amended to extend maturity to February 28, 2024 and increase the interest rate to 12%. The company also has a secured promissory note with a net balance of approximately $4.80 million, maturing November 30, 2023, and secured by a lien on company assets.
Material Changes Versus the Prior Comparable Period
- Quarterly net loss improved by $1.87 million, or 30%, and nine-month net loss improved by $6.71 million, or 29%, primarily because the prior-year periods included contingent-consideration fair-value expense.
- Research and development expense decreased by $973,000 in the quarter and $3.43 million for the nine-month period, reflecting lower collaboration, consulting and laboratory costs and reduced spending on abandoned product candidates.
- General and administrative expense increased by $1.01 million in the quarter and $1.20 million for the nine-month period, driven by higher accounting, legal, compensation and related costs.
- Cash declined $6.22 million from June 30, 2022, and working capital moved from positive $3.11 million to negative $7.85 million.
- The company received $1.63 million from warrant exercises and $2.48 million from a March 2023 private placement during the nine months. Including $228,000 received on April 11, 2023, total private-placement proceeds were $2.71 million.
- Shares outstanding increased to 57,983,591 at March 31, 2023 from 53,007,082 at June 30, 2022. The private placement also issued warrants to purchase 1,189,036 shares in total, including the subsequent April issuance.
- The contingent consideration liability was fully extinguished by December 31, 2022. The company recognized a $419,000 loss on extinguishment during the nine months.
Outlook, Risks and Unusual Items
Management states that the company has never generated revenue and does not expect revenue until product candidates receive regulatory approval and are commercialized. No formal financial guidance is provided.
The financial statements include a substantial doubt regarding the company’s ability to continue as a going concern for one year after issuance. Management expects to seek additional equity or debt financing to fund research and development, personnel, equipment, regulatory work and working capital. Failure to obtain financing could require material reductions or suspension of operations. Additional equity financing could materially dilute existing stockholders.
Management has reduced overhead, streamlined personnel and prioritized oncology and the HIV therapeutic vaccine program. The company stated an intention to pursue an IND submission for ENOB-DC11 in early or mid-2024, subject to successful preclinical and process-development work. It also described potential pre-IND activity for ENOB-HV12 in late 2023 to early 2024, but these timelines are forward-looking and uncertain.
- The company recorded no additional impairment through March 31, 2023, but carried $61.57 million of indefinite-lived license-related IPR&D assets and $11.64 million of goodwill. The company recorded a $93.25 million IPR&D impairment in fiscal 2022.
- Pending litigation includes a securities class action, federal and state derivative actions, a company lawsuit alleging misrepresented or fabricated study results, a demand exceeding $64 million under an investor-rights agreement, and a separate former-CFO-related claim. The filing does not quantify probable losses or provide a clear estimate of potential exposure.
- The company’s disclosure controls and procedures were deemed ineffective because of a material weakness related to insufficient resources for complex accounting matters.
- The company terminated its sublease effective April 30, 2023 and disclosed a $175,000 termination payment, a subsequent event after the reporting date.
Investor Verification Priorities
- Verify the issuer and period: the source is an Enochian Biosciences Inc. Form 10-Q for March 31, 2023, not a Lunai Bioworks Inc. filing or a 2022 third-quarter filing.
- Assess liquidity and funding runway given $2.95 million of cash, negative $7.85 million of working capital, recurring losses and substantial going-concern doubt.
- Review debt maturities, the 12% convertible notes due February 2024, the secured promissory note due November 2023 and the lien over company assets.
- Evaluate dilution from the March 2023 private placement, warrant issuances, stock options and potential future financing.
- Review the status and potential financial impact of the disclosed securities, derivative, contractual and former-CFO litigation.
- Validate the company’s clinical, regulatory and financing timelines, which remain dependent on preclinical results, FDA interactions and access to additional capital.
- Consider the material weakness in disclosure controls and the substantial intangible-asset balances when assessing reported book value.